Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-11-01 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing FDA approval of a drug (Afinitor) for a specific medical condition, including study details, safety information, and forward-looking statements. There are no financial statements, detailed financial performance data, or comprehensive management analysis typical of annual or interim reports. The document is not a transcript, audit report, or governance information. It is a regulatory filing providing material news about the company but does not fit into categories like earnings release or capital update. Given the nature of Form 6-K filings and the content being a press release about regulatory approval, the best classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2010-11-01 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing Phase III clinical trial data for the Menveo vaccine, including detailed clinical results, safety information, and future regulatory plans. There are no financial statements, earnings highlights, or management discussion of financial results. The document is not an annual or interim report, nor is it a transcript, audit report, or governance-related filing. It is a regulatory filing used by foreign companies to report material information to the SEC between annual reports. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2010-10-26 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the approval of Lucentis for diabetic macular edema in the EU. It includes clinical trial data summaries, forward-looking statements, company background, and contact information. There are no financial statements, detailed financial analysis, or comprehensive report data. The document is an announcement of a corporate event and related information rather than a full financial report or regulatory filing with substantive financial data. It is not an earnings release, annual report, or interim report. The document is longer than 5,000 characters but is essentially a press release filed as a Form 6-K. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2010-10-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing Phase III clinical trial results for an influenza vaccine. It is not a full annual or quarterly report, nor an earnings release. It is a regulatory filing to disclose material information to the SEC and investors. The document is lengthy (15,000 characters) and contains detailed clinical trial data and corporate information, but it is not a financial report or management discussion. Form 6-K filings are typically classified as Regulatory Filings (RNS) in this taxonomy because they are miscellaneous reports submitted by foreign private issuers that do not fit into other specific categories like 10-K, IR, ER, etc.
2010-10-22 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, a foreign private issuer, submitted to the SEC. It contains detailed financial results for the third quarter and nine months ended September 30, 2010, including net sales, operating income, net income, EPS, and core operating income. It discusses business performance, product launches, regulatory approvals, and pipeline updates. The presence of comprehensive financial data and analysis for a quarterly period indicates this is a quarterly interim report. Form 6-K is commonly used by foreign private issuers to report interim financial information. The document is lengthy (15,000 characters) and contains substantive financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2010-10-21 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes detailed financial performance data for the third quarter and nine months ended September 30, including net sales, operating income, net income, EPS, and core operating income. It also discusses product approvals, pipeline updates, and strategic priorities. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly and nine months). This matches the definition of an Interim / Quarterly Report (IR). It is not a full annual report (10-K or 20-F), nor is it a brief announcement or certification. Therefore, the correct classification is IR with high confidence.
2010-10-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.